A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis

Neurology
N Koch-HenriksenDanish Multiple Sclerosis Group

Abstract

To investigate whether the efficacy of interferon-beta (IFNbeta) treatment of relapsing-remitting MS (RR-MS) was influenced by type, dose, and frequency of administration. From June 1996 through October 1997, the authors offered participation to all Danish RR-MS patients who met the following criteria: definite MS, at least two relapses within 2 years, age 18 to 55, and an Expanded Disability Status Scale (EDSS) score of < or = 5.5. The study was multicenter, controlled, open-label, randomized, head-to-head comparing IFNbeta-1a 22 microg once a week (n = 143) with IFNbeta-1b 250 microg every other day (n = 158), both subcutaneously, for 24 months. Patients who declined randomization were offered treatment with IFNbeta-1b 250 microg every other day (n = 120). The primary end-points were the annualized relapse rate, the time to first relapse, and neutralizing antibody formation. The secondary endpoint was time to sustained progression. The annual relapse rates were virtually equal in the two arms of the randomized study (IFNbeta-1a: 0.70; IFNbeta-1b: 0.71); so were the time to first relapse and the time to sustained progression. In the nonrandomized patients (IFNbeta-1b), the annual relapse rate was not significantly different, b...Continue Reading

Citations

Dec 1, 2006·Der Nervenarzt·Peter Rieckmann, Peter Rieckmann
Nov 16, 2007·Journal of Neurology·Christoph KleinschnitzHeinz Wiendl
Nov 14, 2008·Journal of Neurology·UNKNOWN Multiple Sclerosis Therapy Consensus Group (MSTCG)R Hohlfeld
Dec 25, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Corey A McGraw, Fred D Lublin
Feb 21, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Dimitrios Karussis
Sep 16, 2008·Lancet Neurology·Per Soelberg Sørensen
Sep 16, 2009·Journal of Immunotherapy·Takaya TsunoKathryn C Zoon
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Francesco ManfredoniaFabio Monzani
Jul 16, 2010·Neuropsychiatric Disease and Treatment·David W Brandes
Apr 25, 2014·Current Opinion in Neurology·Per Soelberg Sorensen
Sep 4, 2014·Advances in Therapy·Martin Marziniak, Sven Meuth
Aug 27, 2009·Biologics : Targets & Therapy·Angela Applebee, Hillel Panitch
Aug 27, 2009·Biologics : Targets & Therapy·Damiano PaolicelliMaria Trojano
Mar 28, 2009·Journal of Neurology·Peter Flachenecker, Kristin Stuke
Mar 14, 2012·Current Opinion in Neurology·Aaron E Miller, Robert W Rhoades
Mar 8, 2007·Expert Review of Neurotherapeutics·Mathias Buttmann, Peter Rieckmann
Dec 22, 2006·Expert Review of Neurotherapeutics·Simone FerreroNicola Ragni
Apr 13, 2010·Expert Review of Clinical Immunology·Masaaki Niino, Hidenao Sasaki
Mar 8, 2011·Expert Review of Neurotherapeutics·Hans-Peter HartungTomas Olsson
Aug 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Sum LamMalcolm Gottesman
Aug 13, 2008·Expert Opinion on Biological Therapy·Bianca Weinstock-GuttmanRobert Zivadinov
May 26, 2009·Expert Opinion on Pharmacotherapy·Aaron Boster, Michael K Racke
Feb 24, 2009·Current Medical Research and Opinion·S Mitchell Freedman
Jun 16, 2011·Current Medical Research and Opinion·Bernard M J UitdehaagDaniel D Mikol
Dec 25, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jens IngwersenHans-Peter Hartung
Aug 23, 2012·Neurological Research·Saeed Talebzadeh NickAlireza Minagar
Sep 3, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Seidu InusahGary R Cutter
Dec 29, 2016·Current Medical Research and Opinion·Thomas R EinarsonMárcio Machado
Dec 7, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Tomas KalincikUNKNOWN MSBase Study Group
Nov 14, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Dima Dahdaleh, Basil Sharrack
Jan 18, 2012·Multiple Sclerosis : Clinical and Laboratory Research·G GiovannoniE Waubant
Apr 7, 2018·Expert Opinion on Biological Therapy·Laura DumitrescuRadu Tanasescu
Sep 19, 2015·The Cochrane Database of Systematic Reviews·Irene TramacereGraziella Filippini
Jun 8, 2013·The Cochrane Database of Systematic Reviews·Graziella FilippiniGeorgia Salanti
Nov 16, 2017·PharmacoEconomics·Livia Lovato Pires de LemosFrancisco de Assis Acurcio
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Loredana La MantiaGraziella Filippini
Feb 5, 2021·Current Medical Research and Opinion·Zbyšek PavelekMartin Vališ
Jun 13, 2006·Multiple Sclerosis : Clinical and Laboratory Research·Per Soelbeg SorensenUNKNOWN Danish Multiple Sclerosis Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.